Hot Pharma Stocks / Ideen / Blockbuster

11'626 posts / 0 new
Letzter Beitrag
Laser02
Bild des Benutzers Laser02
Offline
Zuletzt online: 10.11.2011
Mitglied seit: 11.02.2009
Kommentare: 386
Re: PATH 2.10$

Aurum wrote:

Vagnum wrote:
Quote:
Wedbush Lowers PT on NuPathe from 20$ to 17$ and maintains its Outperform rating.

buy signal?

target 2.45-2.70$

Pre-market: 2.09 -1.96 (-48.38%)

Target 17$ - Das wäre ne nette Performance

Seit ihr eingestiegen ???

vagnum
Bild des Benutzers vagnum
Offline
Zuletzt online: 11.12.2013
Mitglied seit: 28.01.2009
Kommentare: 3'319
PATH 2.65$

PATH Preisziel erreicht. war gut das Wedbush mit der Empfehlung kam, das hat die nötige Sicherheit gegeben.

Aber jetzt wohin gehts du PATH? Die Shorts covern hier unten, keine Frage und die 2.46$ cash per share waren ein guter Anhaltspunkt. Sollte PATH über 2.80$ gehen, könnte es sein das wir 3.20$ sehen. CIGX habe ich zu früh verkauft. Weiss nicht ob das etwas zu bedeuten hat oder ob das schon war, aber laut Biomedreports Kalender sind Phase 3 Daten einer 2ten Studie auf denn 01.09.2011 zu erwarten.

http://img200.imageshack.us/img200/7638/patha.png

bubble gum?

vagnum
Bild des Benutzers vagnum
Offline
Zuletzt online: 11.12.2013
Mitglied seit: 28.01.2009
Kommentare: 3'319
Re: PATH 2.10$

Aurum wrote:

Pre-market: 2.09 -1.96 (-48.38%)

Target 17$ - Das wäre ne nette Performance

schon ja aber wer weiss was in einem Jahr sein wird und ne KE dürfte es Mitte 2012 auch noch geben, plus das Patch müsste sich auch noch verkaufen. Von der Aktienstruktur her ist dieser Titel aber mehr als gut geeignet um so eine Performance hinzulegen. Per Yahoo, 4.7 Mill float.

News:

Leerink Swann Cuts Valuation on NuPathe (PATH), Sees Approval of Zelrix Now Between 1 and 2 Years

http://bit.ly/p2LtHf

Laser02 wrote:

Seit ihr eingestiegen ???

jejo 2.79$

EDIT: out PATH 2.65$

bubble gum?

MT85
Bild des Benutzers MT85
Offline
Zuletzt online: 20.12.2011
Mitglied seit: 12.01.2010
Kommentare: 73
Hot Pharma Stocks / Ideen / Blockbuster

PATH 2.82$ +6%

vagnum
Bild des Benutzers vagnum
Offline
Zuletzt online: 11.12.2013
Mitglied seit: 28.01.2009
Kommentare: 3'319
LGND

Ligand Pharmaceuticals Incorporated Partner GlaxoSmithKline plc Receives Positive Data From Promacta PIII ENABLE1 Study In Hepatitis C-Related Thrombocytopenia

Quote:

Tuesday, 26 Jul 2011 07:15am EDT

Ligand Pharmaceuticals Incorporated announced that its partner GlaxoSmithKline plc has announced that it received positive data from ENABLE-1, the first of two Phase III studies examining Promacta (eltrombopag) in patients with hepatitis C-related thrombocytopenia, and that full data will be released at an upcoming scientific conference.

http://www.reuters.com/finance/stocks/LGND.O/key-developments/article/23...

bubble gum?

vagnum
Bild des Benutzers vagnum
Offline
Zuletzt online: 11.12.2013
Mitglied seit: 28.01.2009
Kommentare: 3'319
Re: Yongye International Inc (Public, NASDAQ:YONG)

b00n wrote:

zwar china, aber iwie doch interessant.

4.55

52 week 3.01 - 9.49

div. sachen in der pipe

Experiment Summary of the Effect of

Yongye Plant Nutrient on Tobacco

Summary Report on the Demonstration of Potato Applied with Yongye Plant Nutrient

.... http://www.yongyeintl.com/Publications.html

bereits aufm markt;

http://www.yongyeintl.com/Plant_Products.html

-----

Second Quarter 2011 Financial Highlights

Revenue in the second quarter of 2011 increased 73.0% to $154.7 million from $89.4 million for the same period of 2010

Gross profit increased 83.4% year-over-year to $91.8 million

Income from operations increased 72.5% to $51.5 million

Net income attributable to Yongye increased 63.1% to $39.5 million, or $0.77 per diluted share, compared to $24.2 million, or $0.54 per diluted share, in the same period last year

Adjusted net income attributable to Yongye, which excludes non-cash expenses related to share-based compensation for management and independent directors, the amortization of the acquired Hebei customer list, and a change in the fair value of derivative liabilities, was $40.5 million, or $0.82 per diluted share, compared to $24.1 million, or $0.54 per diluted share, in the same period last year*

ja ich bin eigetl. wegen folgendem darauf gekommen: :!:

läuft sehr gut seit deinem alert. gratuliere. :roll:

bubble gum?

vagnum
Bild des Benutzers vagnum
Offline
Zuletzt online: 11.12.2013
Mitglied seit: 28.01.2009
Kommentare: 3'319
REGN 65.70$

noch was grösseres mit super Performance.

INSIGHT-Next big drug against cholesterol takes shape

BETS ON A MAGIC BULLET

Quote:

The clearest advantage so far has been seen in Regeneron's new drug. Data from initial studies suggests REGN727 may be able to reduce LDL by another 50 percent when used in combination with statins, which themselves can cut LDL in half.

"Regeneron's anti-PCSK9 antibody really looks like a magic bullet against LDL cholesterol" said Ziad Bakri, a biotechnology analyst with T. Rowe Price. His firm is one of Regeneron's largest shareholders, with a 9.5 percent stake as of the end of June.

Assuming longer-term studies demonstrate the drug is safe and prevents heart attacks and stroke, Bakri estimates it could capture annual sales "in the billions of dollars" if approved.

"Taking advantage of this pathway is a creative leap forward," said Dr. Kristin Newby, a Duke University heart researcher who has no involvement in PCSK9 research.

But she cautioned that other classes of novel medicines have stumbled because of unexpected safety problems....

click the link um weiter zu lesen.

http://www.reuters.com/article/2011/08/29/health-cholesterol-idUSN1E77L1...

bubble gum?

b00n
Bild des Benutzers b00n
Offline
Zuletzt online: 09.05.2020
Mitglied seit: 15.02.2010
Kommentare: 5'227
Re: Yongye International Inc (Public, NASDAQ:YONG)

Vagnum wrote:

b00n wrote:
zwar china, aber iwie doch interessant.

4.55

52 week 3.01 - 9.49

div. sachen in der pipe

Experiment Summary of the Effect of

Yongye Plant Nutrient on Tobacco

Summary Report on the Demonstration of Potato Applied with Yongye Plant Nutrient

.... http://www.yongyeintl.com/Publications.html

bereits aufm markt;

http://www.yongyeintl.com/Plant_Products.html

-----

Second Quarter 2011 Financial Highlights

Revenue in the second quarter of 2011 increased 73.0% to $154.7 million from $89.4 million for the same period of 2010

Gross profit increased 83.4% year-over-year to $91.8 million

Income from operations increased 72.5% to $51.5 million

Net income attributable to Yongye increased 63.1% to $39.5 million, or $0.77 per diluted share, compared to $24.2 million, or $0.54 per diluted share, in the same period last year

Adjusted net income attributable to Yongye, which excludes non-cash expenses related to share-based compensation for management and independent directors, the amortization of the acquired Hebei customer list, and a change in the fair value of derivative liabilities, was $40.5 million, or $0.82 per diluted share, compared to $24.1 million, or $0.54 per diluted share, in the same period last year*

ja ich bin eigetl. wegen folgendem darauf gekommen: :!:

läuft sehr gut seit deinem alert. gratuliere. :roll:

juo thx. 5.5 muss fallen

b00n
Bild des Benutzers b00n
Offline
Zuletzt online: 09.05.2020
Mitglied seit: 15.02.2010
Kommentare: 5'227
Hot Pharma Stocks / Ideen / Blockbuster

samy wrote:

Was haltet Ihr von der Firma?

Der Kurs ist momentan bei 3.77$

Neurogesx NGSX Wedbush Outperform tgt $10

Neurogesx NGSX Ladenburg Thalmann Buy $16

NeurogesX Wins Big Approval

By Jason Napodano, CFA

Companies:Neurogesx, Inc.

FDA Approves NeurogesX's Qutenza

NeurogesX (NasdaqGM: NGSX - News) announced that the U.S. FDA had approved Qutenza (capsaicin patch) for the management of neuropathic pain due to postherpetic neuralgia (PHN). We expect management to spend the next several months preparing for the launch by facilitating reimbursement procedure, establishing distribution channels, hiring and training the specialty sales force, and conducting the manufacturing for commercial supply.

Key to our bullish sales forecast for the drug will be establishing a permanent reimbursement code for both the product and application, as Qutenza requires administration by a physician or healthcare professional.

Qutenza is a cutaneous (skin) patch designed to treat peripheral neuropathic pain conditions. The Qutenza patch provides a pure high concentration (8%) of a synthetic capsaicin, known as trans­-capsaicin, directly to the site of pain via a rapid-delivery cutaneous delivery system designed to provide three months of relief with minimal potential for side effects, abuse, or drug-drug interactions.

Qutenza has been studied in roughly 2,500 patients during its clinical program. Clinical studies have shown that PHN pain can be reduced for up to 12 weeks following a single one hour treatment. In the phase III PHN trial, patients administered Qutenza saw an average 30% to 32% reduction in pain vs. 20% to 24% for the control. Additionally, a significant number of patients on Qutenza demonstrated greater than a 30% reduction in pain over the course of treatment.

We believe management’s goal in the U.S. is to promote the product through an in-house specialty sales force -- eventually that may grow to the size of 80 to 100 representatives. The company has spent the last few months expanding the senior management team to bring in directors of marketing, commercial operations, sales and business development.

Management also recently conducted a qualitative and quantitative marketing study in preparation of approval. As of now, our financial model assumes a launch during the first half of 2010 with a small specialized sales force of around 20 to 25 representatives. This group will target the top quartile or so of the 5,000 pain centers and 10,000 neurologists that are high-prescribers for PHN. When progress is made here, management will probably look to expand through expansion of the force or signing a co-promotion agreement.

Outside the U.S., NeurogesX has partnered Qutenza with Japanese large-cap pharmaceutical company Astellas. NeurogesX received approval for Qutenza in the European Union in May 2009. The deal with Astellas includes all 27 EU member states, plus Iceland, Norway, Liechtenstein and Switzerland, along with the Middle East and Africa. Astellas plans to be ready to launch the product during the first half of 2010, and will pay NeurogesX a scaling mid-teen to mid-twenty percent royalty on sales.

We continue to be positive on NeurogesX. We are maintaining our Outperform rating and expect the share to trade upwards towards are $12 target over the near-term.

vagnum
Bild des Benutzers vagnum
Offline
Zuletzt online: 11.12.2013
Mitglied seit: 28.01.2009
Kommentare: 3'319
DSCO

Discovery Labs Submits SURFAXIN® Complete Response To FDA

Quote:

WARRINGTON, Sept. 6, 2011 /PRNewswire/ — Discovery Labs, Inc. (NASDAQ:DSCO) today announced that, on September 2, 2011, it submitted its Complete Response to the 2009 Complete Response Letter issued by the U.S. Food and Drug Administration (FDA) for SURFAXIN® (lucinactant) for the prevention of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that the FDA will designate the Complete Response as a Class 2 resubmission of the SURFAXIN New Drug Application (NDA), which would result in a target review period of six months and potential approval of SURFAXIN in the first quarter of 2012. If approved, SURFAXIN would represent the first synthetic, peptide-containing surfactant for use in neonatal medicine.

In April 2009, Discovery Labs received from the FDA a Complete Response Letter, which contains the requirements that must be addressed to gain U.S. marketing approval for SURFAXIN. The safety and efficacy of SURFAXIN for the prevention of RDS in premature infants has been previously demonstrated in a large, multinational Phase 3 clinical program. The Complete Response Letter did not question the quality of the clinical trial data or call for additional clinical trials to demonstrate the safety or efficacy of SURFAXIN. The Complete Response Letter focused primarily on certain aspects of an important quality control release and stability test for SURFAXIN, the fetal rabbit biological activity test (BAT). Discovery Labs believes that a key step to potentially gain FDA marketing approval for SURFAXIN is to satisfy the FDA’s requirements for final validation of the BAT. Accordingly, Discovery Labs has completed a comprehensive preclinical program intended to meet the FDA’s requirements and has included these data in its Complete Response.

“We have had several productive interactions with the FDA related to our SURFAXIN comprehensive preclinical program to support the Complete Response,” said W. Thomas Amick, Chairman of the Board and Chief Executive Officer, Discovery Labs. “Based on these interactions, we believe we have addressed all requirements of the 2009 Complete Response Letter.”

In accordance with FDA guidance, Discovery Labs expects that it will be notified within 14 days that the Complete Response is deemed “complete” and the classification of the submission, which, under the Prescription Drug User Fee Act, will determine the target action date (PDUFA date) for the FDA to complete its review of the SURFAXIN NDA. Upon receipt of this notification, Discovery Labs plans to hold an investor conference call to provide an overview of the comprehensive preclinical program and the SURFAXIN Complete Response

http://bit.ly/oKHrwZ

bubble gum?

vagnum
Bild des Benutzers vagnum
Offline
Zuletzt online: 11.12.2013
Mitglied seit: 28.01.2009
Kommentare: 3'319
MELA 3.57

MELA Sciences, Inc. Receives European Union Approval for MelaFind

Quote:

MELA Sciences, Inc. announced that it received CE Mark approval for MelaFind, allowing the Company to market its MelaFind device to dermatologists across the European Union (EU). The Company intends to initially market MelaFind in Germany, which has the highest incidence of melanoma in Europe.

http://www.reuters.com/finance/stocks/MELA.O/key-developments

bubble gum?

b00n
Bild des Benutzers b00n
Offline
Zuletzt online: 09.05.2020
Mitglied seit: 15.02.2010
Kommentare: 5'227
Hot Pharma Stocks / Ideen / Blockbuster

Rexahn Pharmaceuticals, Inc.

(Public, AMEX:RNN)

wieder auf *trab* seit paar tagen. News kamen auch. hab paar unter 1 buck. könnte durchaus weiterlaufen.. ich denk trial ergebnisse sind überfällig.

wisst ja bin alter rnn fan, der freundin hab ich auch paar ins depot gelegt

grüessli id rundi

b00n
Bild des Benutzers b00n
Offline
Zuletzt online: 09.05.2020
Mitglied seit: 15.02.2010
Kommentare: 5'227
Re: Yongye International Inc (Public, NASDAQ:YONG)

b00n wrote:

Vagnum wrote:
b00n wrote:
zwar china, aber iwie doch interessant.

4.55

52 week 3.01 - 9.49

div. sachen in der pipe

Experiment Summary of the Effect of

Yongye Plant Nutrient on Tobacco

Summary Report on the Demonstration of Potato Applied with Yongye Plant Nutrient

.... http://www.yongyeintl.com/Publications.html

bereits aufm markt;

http://www.yongyeintl.com/Plant_Products.html

-----

Second Quarter 2011 Financial Highlights

Revenue in the second quarter of 2011 increased 73.0% to $154.7 million from $89.4 million for the same period of 2010

Gross profit increased 83.4% year-over-year to $91.8 million

Income from operations increased 72.5% to $51.5 million

Net income attributable to Yongye increased 63.1% to $39.5 million, or $0.77 per diluted share, compared to $24.2 million, or $0.54 per diluted share, in the same period last year

Adjusted net income attributable to Yongye, which excludes non-cash expenses related to share-based compensation for management and independent directors, the amortization of the acquired Hebei customer list, and a change in the fair value of derivative liabilities, was $40.5 million, or $0.82 per diluted share, compared to $24.1 million, or $0.54 per diluted share, in the same period last year*

ja ich bin eigetl. wegen folgendem darauf gekommen: :!:

läuft sehr gut seit deinem alert. gratuliere. :roll:

juo thx. 5.5 muss fallen

MS kauft weiter ein..

vagnum
Bild des Benutzers vagnum
Offline
Zuletzt online: 11.12.2013
Mitglied seit: 28.01.2009
Kommentare: 3'319
Gen X Stymied By Baby Boomers In Jobs

interessant...

http://de.wikipedia.org/wiki/Generation_X

Quote:

September 15, 2011

Gen X Stymied By Baby Boomers In Jobs

(Bloomberg News) In Tiffany Spaulding’s 12 years in the pharmaceutical industry, she’s worked for three companies, two of which no longer exist, and relocated to four states.

Now 39 and living in Brookfield, Connecticut, she hasn’t had a promotion in five years and says she sees no chance to advance, stuck behind a wall of baby boomers. She would quit and turn her hobby of jewelry design into a business, she says, if not for the home and school loans that eat up half her salary.

Spaulding, according to a new report, is a typical member of the relatively small group called Generation X, 46 million Americans born between 1965 and 1978: They’re ambitious, squeezed by debt and frustrated by people who aren’t retiring on schedule. More than a third hope to leave their jobs in three years, a survey of more than 1,100 members of Generation X by the Center for Work-Life Policy found.

Twenty-eight percent say they are working longer hours, an average of 10 more a week than three years ago, and credit card debt helps dictate career choices for 74 percent, according to the center’s report, based on research including interviews with Spaulding and 200 others.

“They are being leaned on from all sides,” says Sylvia Ann Hewlett, a co-author of the report and the founder of the center, based in New York. “They don’t think that there is necessarily a clear set of opportunities ahead of them in corporate America, so there is a lot of flight risk.”

The group’s moniker was popularized by Douglas Coupland’s 1991 novel “Generation Secret Tales for an Accelerated Culture,” and its members were epitomized as apathetic and directionless in films such as “Slacker” in 1991 and 1994’s “Reality Bites.” They long ago shed that image, Hewlett says, and as they approach middle age pose challenges to companies that need “bench strength for leadership.”

They have different expectations -- and demands -- of employers, according to the report, prizing independence and flexible hours more than their predecessors.

While their experiences and complaints are shared by other generations, the report says that for this group, trends such as the rising cost of higher education have hit particularly hard. It says those entering college in 1996 had average expenses more than four times higher than boomers 20 years earlier.

Many began their careers as companies started cutting back on pensions and health care benefits, and while people in Generation X are more educated and more diverse than boomers, they have had “no welcome in the economy,” says Neil Howe, a demographer and co-author of six books on generations in the U.S., including 2010’s “Millennials in the Workplace.”

‘Financial Disaster’

Even those who aren’t stalled at work can feel pressured by the lingering effects of the worst economic slump in seven decades on a generation that has had rotten timing.

“You look at our generation and we’re on the cusp of financial disaster, and it’s the first time that the American dream isn’t what we all thought it was,” says Bryce Pickering, who has worked at Citigroup Inc. in New York for 10 years and, at 32, is among its youngest managing directors.

“A lot of my friends have been caught up in a bad cycle of graduating at the wrong time, starting in a field that blew up, deciding to go back to school and getting into debt to do that, buying a house that’s now worth half what they bought it for.”

On the job, the report says, Pickering’s cohort is running up against the “behemoth” baby boomer generation of 78 million Americans. Forty-seven percent of this group view themselves as in mid-career and 68 percent believe there’s still time for promotions, according to the center. And coming up behind Generation X is “Generation Y,” at 70 million strong.

Generation X -- whose members include Google founders Larry Page and Sergey Brin, both 38, and Facebook Inc. Chief Operating Officer Sheryl Sandberg, 42 -- is much smaller than its predecessor. “When boomers were in middle management, they didn’t have pressure from Generation X leapfrogging them because it’s not a huge group,” says Hewlett, who is the director of the Gender and Policy Program at Columbia University’s School of International and Public Affairs. “We think that Generation X is certainly feeling this more strongly because the boomers are delaying retirement.”

Todd England, an air traffic controller, says he’s “stuck in the middle,” unable to become a supervisor because older managers need him to train younger controllers.

“We’re like the layer in between the cookies,” says England, 46, who works in Los Angeles. “Unless we actually step up to the plate and take management and leadership roles, we will be the forgotten generation.”

Birgit Neu, chief operating officer for corporate development for global banking and markets at HSBC Holdings Plc in London, says she has also felt the pressure. Neu, 41, started studying for a business degree at New York University in 1987, the month before stock markets crashed and the Dow Jones Industrial Average lost a record 23 percent in one day.

The Philadelphia native graduated into the recession of the early 1990s and worked in publishing, then moved into the dot- com industry, holding three jobs during the Internet bubble and weathering the contraction that followed at a brokerage.

A single mother who often negotiates work from her Blackberry while pushing her four-year-old son on the playground swing, she says she is very aware of HSBC’s younger generation.

“I’ve been doing talks to the grads as they walk in now, in their early 20s,” she says. “I think out to 20 years from now, and one of these people theoretically may be my boss.”

She says her experience has taught her that to avoid getting stalled, “you don’t want to stay in one box.”

Talent War

“Don’t be dependent on anything or anyone,” Neu says. “It’s safest to plan as if the government isn’t going to take care of me, companies aren’t going to take care of me.”

The center’s Generation X survey found 41 percent are unsatisfied with their rate of advancement and 49 percent feel stalled in their careers.

The findings come at time when businesses say it’s increasingly difficult to find qualified workers, according to Milwaukee-based ManpowerGroup, a provider of temporary employees. In the U.S., 52 percent of employers reported having trouble filling positions this year, up from 14 percent in 2010, according to a ManpowerGroup survey.

That makes workers in Generation X, a third of whom have a bachelor’s degree or higher and the youngest of whom have been in the workforce for about a decade, a key pool for companies, the report says.

“These are the next generation of leaders, and if we’re not taking care of their needs and wants, how are we going to retain them?” says Michelle Gadsden-Williams, Zurich-based managing director and global head of diversity and inclusion at Credit Suisse Group AG, the Zurich-based investment bank. “There is definitely a war for talent out there.”

The Generation X survey found that 70 percent would prefer to be their own bosses. They want the flexibility that will allow them to devote time to outside pursuits and family obligations. Less rigid hours and less time spent in the office are very important to 66 percent of women and 55 percent of men in the study, though 43 percent of women and 32 percent of men surveyed do not have children.

For those with children, Generation X members are as extreme at home as they are at work as they try to be the kind of involved parents that many of them -- the first generation of “latchkey” kids -- did not have, according to the report. Sixty-five percent of women and 59 percent of men surveyed feel guilty about the time they spend away from their children, the study found.

“They’re trying to create this island of security for their kids, and that creates tension,” demographer Howe says. “They’re running around taking all these risks while they’re trying to create the opposite life for their kids.”

Credit Suisse began more actively promoting flexible arrangements last year within its finance group, expanding from a focus on working mothers to all employees, Gadsden-Williams says, and over 95 percent of requests are granted.

In May, Credit Suisse started a new effort designed by Gadsden-Williams to train senior female employees, and that she says provides the kind of experience Generation X wants.

Twenty-nine women are participating in an 18-month program that gives them a chance to work in teams with senior executives on special projects, one of which is to assess strategies for attracting and retaining talent among Generation Y. Credit Suisse was one of five sponsors of the Center for Work-Life Policy study, along with American Express Co., Boehringer Ingelheim USA, Cisco Systems Inc. and Google Inc.

At Cisco, workers may take leave of up to 12 months and keep their benefits and jobs, which employees most often use to have children and take care of elderly parents, according to Annmarie Neal, Cisco’s Denver-based chief talent officer.

In 2007, the San Jose, California-based maker of networking equipment began teaming up people in different departments for 16 weeks at a time to develop new strategic products or initiatives. Participants have priority consideration for leadership roles within the company, Neal says.

“With the baby boomers either retiring or just darn tired, there’s a high reliance on Gen-X and Gen-Y to bring energy and innovation into the organization, and just by virtue of their relative maturity we draw more on Gen-X,” she says.

At PepsiCo Inc., “our talent strategy incorporates hiring from all generational cohorts, but our focus on Generation X is laser sharp,” says Paul Marchand, vice president of global talent acquisition at the Purchase, New York-based company. “The next generation of leaders are going to be Gen-Xers, so we’re always looking for ways to attract those who will one day rise to the top layer of our organization.”

One new PepsiCo program helps develop the best prospects for senior management, with six-month assignments that combine business school training with immersion in operations in China, India and Brazil. PepsiCo last year started a career modeling program where employees and managers set goals for assignments three to 10 years out, so people see clear paths to advancement.

Spaulding, who has no children, says she sometimes finds herself saddled with extra work because of an assumption that “work-life balance” only applies to those with kids.

“There are days when I’ve said the corporate environment feels like prison,” says Spaulding, who asked that her employer not be named because she didn’t get permission to be interviewed. “The biggest thing you can offer me, more than salary, more than anything else, is flexibility.”

http://www.fa-mag.com/fa-news/8543-gen-x-stymied-by-baby-boomers-in-jobs...

bubble gum?

b00n
Bild des Benutzers b00n
Offline
Zuletzt online: 09.05.2020
Mitglied seit: 15.02.2010
Kommentare: 5'227
Prana Biotechnology Limited (ADR)

Pre-market: 2.12 +0.40 (23.26%)

September 19, 2011 07:30 ET

Prana's PBT2 Directly Restores Neurons Critical to Cognition

Important Further Demonstration of Mechanism of Action; Journal of Neurochemistry Publication on Biochemical Effects of PBT2 Explains the Preclinical and Clinical Benefits of PBT2 in Alzheimer's Disease

http://www.marketwire.com/press-release/pranas-pbt2-directly-restores-ne...

b00n
Bild des Benutzers b00n
Offline
Zuletzt online: 09.05.2020
Mitglied seit: 15.02.2010
Kommentare: 5'227
SGMO

Sangamo Biosciences, Inc.

(Public, NASDAQ:SGMO)

Sangamo BioSciences Announces Presentation of Groundbreaking Clinical Data From ZFN Therapeutic for HIV/AIDS at ICAAC 2011

http://www.prnewswire.com/news-releases/sangamo-biosciences-announces-pr...

Pre-market: 6.19 +0.19 (3.17%)

b00n
Bild des Benutzers b00n
Offline
Zuletzt online: 09.05.2020
Mitglied seit: 15.02.2010
Kommentare: 5'227
Hot Pharma Stocks / Ideen / Blockbuster

Transcept Pharmaceuticals, Inc.

(Public, NASDAQ:TSPT)

aii verpasst!?

vagnum
Bild des Benutzers vagnum
Offline
Zuletzt online: 11.12.2013
Mitglied seit: 28.01.2009
Kommentare: 3'319
Hot Pharma Stocks / Ideen / Blockbuster

b00n wrote:

Transcept Pharmaceuticals, Inc.

(Public, NASDAQ:TSPT)

aii verpasst!?

jop ich schon.. :roll:

MNTA bounce time

Momenta Hit on Approval of Blood Thinner Rival

http://bit.ly/n3O5Uj

sieht nach 6/6 aus.

EDIT: MNTA shorts in da house. 5/6

bubble gum?

vagnum
Bild des Benutzers vagnum
Offline
Zuletzt online: 11.12.2013
Mitglied seit: 28.01.2009
Kommentare: 3'319
Re: OPTR 14.00$

vagnum wrote:

Am 30 Mai ist FDA Zulassungs Termin. Es gibt hier ein Preisziel von 17.00$ was entweder vor oder bei der Zulassung erreicht werden könnte. Optimer hat seit den letzten Quartalszahlen am 6 Mai 2011, 2.00$ pro Aktie zugelegt. Stand 18 Mai 2011. Das FDA Panel hat mit 13-0 für effizienz und safty abgestimmt.

oder halt nach der Zulassung. low 6.81$ aktuell bei 16.00$

wow...

http://www.dificid.com/

EDIT: Es liegt an den Verkäufen des Medis...

Quote:

The launch is going well, with sales, while small at $3.9 million, doubling analyst estimates.

mehr infos:

http://www.finviz.com/quote.ashx?t=optr

bubble gum?

b00n
Bild des Benutzers b00n
Offline
Zuletzt online: 09.05.2020
Mitglied seit: 15.02.2010
Kommentare: 5'227
OCLS
vagnum
Bild des Benutzers vagnum
Offline
Zuletzt online: 11.12.2013
Mitglied seit: 28.01.2009
Kommentare: 3'319
SIGA 3.10$

SIGA on bounce watch mit Ziel 3.50$

Quote:

Wedbush lowers PT on $SIGA from 23$ to $11, maintains its outperform rating

bubble gum?

b00n
Bild des Benutzers b00n
Offline
Zuletzt online: 09.05.2020
Mitglied seit: 15.02.2010
Kommentare: 5'227
Re: MELA 3.57

vagnum wrote:

MELA Sciences, Inc. Receives European Union Approval for MelaFind

Quote:

MELA Sciences, Inc. announced that it received CE Mark approval for MelaFind, allowing the Company to market its MelaFind device to dermatologists across the European Union (EU). The Company intends to initially market MelaFind in Germany, which has the highest incidence of melanoma in Europe.

http://www.reuters.com/finance/stocks/MELA.O/key-developments

Pre-market: 6.70 +3.52 (110.69%)

vagnum
Bild des Benutzers vagnum
Offline
Zuletzt online: 11.12.2013
Mitglied seit: 28.01.2009
Kommentare: 3'319
Re: SIGA 3.10$

vagnum wrote:

SIGA on bounce watch mit Ziel 3.50$

Quote:

Wedbush lowers PT on $SIGA from 23$ to $11, maintains its outperform rating

SIGA 3.30$ meine 3.50$ sind endlich in play.

bubble gum?

b00n
Bild des Benutzers b00n
Offline
Zuletzt online: 09.05.2020
Mitglied seit: 15.02.2010
Kommentare: 5'227
Hot Pharma Stocks / Ideen / Blockbuster

CXM hat fda zulassung erhalten

vagnum
Bild des Benutzers vagnum
Offline
Zuletzt online: 11.12.2013
Mitglied seit: 28.01.2009
Kommentare: 3'319
Hot Pharma Stocks / Ideen / Blockbuster

b00n wrote:

CXM hat fda zulassung erhalten

war leider nicht dabei... du?

bubble gum?

vagnum
Bild des Benutzers vagnum
Offline
Zuletzt online: 11.12.2013
Mitglied seit: 28.01.2009
Kommentare: 3'319
JAZZ 44.85$

offenes gap bei 44.00$ läuft wenn der Markt läuft mmn.

call 50.00$?

bubble gum?

b00n
Bild des Benutzers b00n
Offline
Zuletzt online: 09.05.2020
Mitglied seit: 15.02.2010
Kommentare: 5'227
Hot Pharma Stocks / Ideen / Blockbuster

ne cxm nicht dabei gewesen.

---

CYCC

PRESS RELEASE

Oct. 13, 2011, 7:00 a.m. EDT

Cyclacel Announces Data Safety Monitoring Board Recommendation to Continue the SEAMLESS Phase 3 Trial of Sapacitabine

Lead-in Portion of the Phase 3 Study Meets Prespecified Criteria Agreed in a SPA With FDA

Leonator
Bild des Benutzers Leonator
Offline
Zuletzt online: 07.08.2020
Mitglied seit: 29.07.2007
Kommentare: 562
ANDS

Zürich (awp) - Der Pharmagigant Roche wird die amerikanische Anadys Pharmaceuticals für rund 230 Mio USD übernehmen. Die beiden Unternehmen hätten eine Vereinbarung über den Zusammenschluss getroffen, wonach Roche Anadys im Rahmen einer Bartransaktion für 3,70 USD je Aktien vollständig übernehme, heisst es in einer Mitteilung am Montag

http://www.google.com/finance?q=NASDAQ:ANDS#

Pre-market: 3.58 +2.54 (244.23%)

b00n
Bild des Benutzers b00n
Offline
Zuletzt online: 09.05.2020
Mitglied seit: 15.02.2010
Kommentare: 5'227
Re: ANDS

Leonator wrote:

Zürich (awp) - Der Pharmagigant Roche wird die amerikanische Anadys Pharmaceuticals für rund 230 Mio USD übernehmen. Die beiden Unternehmen hätten eine Vereinbarung über den Zusammenschluss getroffen, wonach Roche Anadys im Rahmen einer Bartransaktion für 3,70 USD je Aktien vollständig übernehme, heisst es in einer Mitteilung am Montag

http://www.google.com/finance?q=NASDAQ:ANDS#

Pre-market: 3.58 +2.54 (244.23%)

nice, haste abgeräumt?

b00n
Bild des Benutzers b00n
Offline
Zuletzt online: 09.05.2020
Mitglied seit: 15.02.2010
Kommentare: 5'227
Hot Pharma Stocks / Ideen / Blockbuster

b00n wrote:

CXM hat fda zulassung erhalten

läuft weiter

Seiten